Research programme: Gastrointestinal disorder therapeutics - Enterome Bioscience/ Takeda

Drug Profile

Research programme: Gastrointestinal disorder therapeutics - Enterome Bioscience/ Takeda

Alternative Names: EB 120; EB 420

Latest Information Update: 28 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Enterome; Takeda
  • Class
  • Mechanism of Action Gastrointestinal microbiome modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 06 Jan 2016 Enterome Bioscience and Takeda agree to co-develop therapeutics in France for Gastrointestinal disorders
  • 06 Jan 2016 Preclinical trials in Inflammatory bowel disease in France (unspecified route)
  • 06 Jan 2016 Preclinical trials in Ulcerative colitis in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top